UniQure (QURE) Stock Skyrockets 248% After Groundbreaking Huntington’s Trial Results - Analysts Boost Price Targets

Biotech thunderbolt strikes as UniQure's Huntington's disease treatment shows staggering results—sending shares into orbit and Wall Street scrambling to revise projections.

The Catalyst That Changed Everything

Positive clinical trial data triggered an unprecedented 248% surge—one of those rare moments when science slams into markets with sledgehammer force. Trading floors buzzed with the kind of energy usually reserved for crypto bull runs.

Analysts Playing Catch-Up

Price targets got demolished and rebuilt overnight. The Street's usual cautious optimism transformed into full-throated endorsement as the data became clear. Because nothing makes analysts move faster than a stock that's already moved without them.

What's Next for the Rocket Ship

The treatment's success positions UniQure at the forefront of genetic medicine—proving that sometimes the biggest gains come from actually solving real human problems rather than just shuffling digital tokens. Though Wall Street would probably prefer another NFT bubble.

Market watchers now eye whether this surge has legs or if profit-taking will hit—because in biotech, as in crypto, what goes up 248% in a day tends to attract both believers and skeptics in equal measure.

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

UniQure’s trial results are being viewed as a major breakthrough, as currently there are no treatments approved by the U.S. Food and Drug Administration (FDA) for Huntington’s, which is a rare inherited brain disorder that steadily worsens and generally leads to death 10 to 30 years after symptoms begin.

The company also announced that it has entered into a $175 million non-dilutive senior secured term loan facility with Hercules Capital (HTGC), which keeps funds from the outstanding $50 million debt available until 2030 and provides access to an additional $125 million to support the potential commercial launch of AMT-130.

Analysts Raise Price Targets for QURE Stock

Following the favorable development, Leerink analyst Joseph Schwartz raised his price target for UniQure stock to $68 from $48 and reiterated a Buy rating. The 5-star analyst views the topline results from the pivotal Phase 1/2 study of AMT-130 in Huntington’s disease as a “game-changer and a definitive win” for the company. Schwartz continues to see this data as definitive, clearly marking a difference in progression across multiple measures of function and cognition.

Likewise, RBC Capital analyst Luca Issi increased the price target for QURE stock to $55 from $24 and reaffirmed a Buy rating. Issi noted that UniQure shared updated 36-month Huntington’s data that showed a benefit consistent across multiple endpoints. Issi is bullish on UniQure, as it “likely has a drug for a devastating disease that comes with 12x higher risk of committing suicide.”

Additionally, Stifel analyst Paul Matteis increased the price target for UniQure stock to $65 from $30 and reiterated a Buy rating. The 4-star analyst noted that the three-year AMT-130 data suggest a larger market opportunity and a higher probability of approval. Matteis is encouraged by AMT-130 data, given the severity of Huntington’s, the strength of the trial’s efficacy, and UniQure’s “attained alignment” with the FDA ahead of the three-year data.

Is QURE a Good Stock to Buy?

Overall, Wall Street has a Strong Buy consensus rating on UniQure stock based on nine unanimous Buy ratings. The average QURE stock price target of $57.14 indicates 20.3% upside potential.